NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
Clinical Trials
37 trialsNCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT02405858 2025-02-03
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
Janssen Pharmaceutical K.K.
Phase 4 Completed
NCT03643107 2025-01-23
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Allarity Therapeutics
Phase 2 Completed
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT01485861 2023-09-14
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Genentech, Inc.
Phase 1/2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT01992653 2023-03-14
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Genentech, Inc.
Phase 1/2 Completed
NCT02229136 2022-12-01
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
US Oncology Research
Phase 2 Completed
NCT04071262 2021-09-21
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02162771 2020-01-29
rituximab
Celltrion
Phase 3 Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT01685983 2019-03-15
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01200758 2018-11-27
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 3 Completed
NCT01724021 2018-01-23
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
Phase 3 Completed
NCT01756638 2017-10-23
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT01831505 2017-02-27
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Presage Biosciences
Phase 1 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT02074137 2016-06-02
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT01795703 2015-11-04
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
Janssen Research & Development, LLC
Phase 2 Completed
NCT01324583 2015-01-07
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sanofi
Phase 1 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed
NCT00494780 2014-07-11
MUNIN
GlaxoSmithKline
Phase 2 Completed
NCT00638690 2014-04-30
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Cougar Biotechnology, Inc.
Phase 3 Completed
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00985959 2013-12-02
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT00822809 2012-10-03
CASIMAS
Neovii Biotech
Phase 3 Completed